Compare Dyne Therapeutics Inc. Common Stock (DYN) vs Vanguard Emerging Markets Stock Index Fund ETF (VWO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dyne Therapeutics Inc. Common Stock vs Vanguard Emerging Markets Stock Index Fund ETF — how do they compare? Dyne Therapeutics Inc. Common Stock trades at $15.06 (market cap $2.86B), while Vanguard Emerging Markets Stock Index Fund ETF trades at $58.7 (market cap $168.50B). The key difference: Vanguard Emerging Markets Stock Index Fund ETF is far larger — about 58.9× Dyne Therapeutics Inc. Common Stock's market cap, and Vanguard Emerging Markets Stock Index Fund ETF is trading nearer its 52-week high, Dyne Therapeutics Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Dyne Therapeutics Inc. Common Stock for 0 Days and Vanguard Emerging Markets Stock Index Fund ETF for 135 Days on average.
| DYN | VWO | |
|---|---|---|
Market Cap | $2.86B | $168.50B |
Volume | 3,341,579 | 5,873,453 |
Sector | Health | — |
52-Week High | $26.78 | $61.44 |
52-Week Low | $14.60 | $52.42 |
Typical Hold Time | 0 Days | 135 Days |
Enterprise Value | $2.18B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dyne Therapeutics (DYN) trades at $15.30, down 4.14% on the day, reflecting recent volatility amid mixed clinical trial news. The stock is in a neutral technical position with immediate support at $15 and resistance at $16. Fundamentally, the company is a clinical-stage biotech with no revenue, reporting a net loss of $446.21M in 2025, but maintains strong analyst support with an 85.7% buy rating and a $35.20 consensus price target. Recent news highlights progress in Phase 1/2 trials for neuromuscular diseases and a $375M public offering in July 2026 to fund development.
The investment case hinges on clinical success, offering significant upside to the price target, but carries high risk due to pre-revenue status, dependence on trial outcomes, and negative cash flow from operations. Investor sentiment is cautiously optimistic, buoyed by analyst confidence, though volatility from sector-specific news remains a near-term challenge.
VWO trades at $59.68, down slightly by 0.08% today. Technical indicators show a neutral overall signal with bearish moving averages, while RSI readings are neutral. The ETF focuses on emerging markets, with exposure to Taiwan's AI and semiconductor sectors but faces headwinds from China's economic slowdown. Recent news highlights institutional buying interest, such as Allianz increasing its stake by 12.6% in Q3 2026.
Outlook is mixed: AI-driven growth in Taiwan offers upside, but China's weakness and concentration risks pose challenges. The ETF's low expense ratio of 0.06% appeals for cost-conscious investors, yet emerging market volatility requires caution. Key risks include regional economic instability and currency fluctuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Dyne Therapeutics Inc. Common Stock
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company developing therapeutics for genetically driven neuromuscular diseases, including Duchenne muscular dystrophy and myotonic dystrophy type 1, with additional preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease.
Read more on DYN →About Vanguard Emerging Markets Stock Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the FTSE Emerging Markets All Cap China A Inclusion Index. It invests by sampling the index, meaning that it holds a broadly diversified collection of securities that, in the aggregate, approximates the index in terms of key characteristics.
Read more on VWO →
